Studienlage

Die folgenden Studien können als Argumentation für eine Wirksamkeit der Off-Label-Behandlung genutzt werden

• Safe efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study.
• Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19
• Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
• Low-dose Naltrexone Improves post–COVID-19 condition Symptoms
• Low-Dose naltrexone restored TRPM3 ion channel function in natural killer cells from long COVID patients

• Reduced Fatigue Symptoms in the Post-COVID Syndrome With Amifampridine: A Collective Casuistry With Double-Blind Discontinuation Trials

• Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole